We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
- Authors
Marre, M; Shaw, J; Brändle, M; Bebakar, W M W; Kamaruddin, N A; Strand, J; Zdravkovic, M; Le Thi, T D; Colagiuri, S; LEAD-1 SU study group
- Abstract
To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
- Publication
Diabetic medicine : a journal of the British Diabetic Association, 2009, Vol 26, Issue 3, p268
- ISSN
1464-5491
- Publication type
Journal Article
- DOI
10.1111/j.1464-5491.2009.02666.x